NFE2L3 and ovarian serous cystadenocarcinoma: NFE2L3 was also demonstrated to be localized in the nucleoplasm and vesicles (Figure 2A), and the protein expression level of NFE2L3 was significantly higher in ovarian serous cystadenocarcinoma (OV), TGCT, LUSC, and CESC than in normal tissues (Figure 2B).